Radiomic Models Based on Magnetic Resonance Imaging Predict the Spatial Distribution of CD8 Tumor-infiltrating Lymphocytes in Breast Cancer
Overview
Affiliations
Infiltration of CD8 T cells and their spatial contexture, represented by immunophenotype, predict the prognosis and therapeutic response in breast cancer. However, a non-surgical method using radiomics to evaluate breast cancer immunophenotype has not been explored. Here, we assessed the CD8 T cell-based immunophenotype in patients with breast cancer undergoing upfront surgery (n = 182). We extracted radiomic features from the four phases of dynamic contrast-enhanced magnetic resonance imaging, and randomly divided the patients into training (n = 137) and validation (n = 45) cohorts. For predicting the immunophenotypes, radiomic models (RMs) that combined the four phases demonstrated superior performance to those derived from a single phase. For discriminating the inflamed tumor from the non-inflamed tumor, the feature-based combination model from the whole tumor (RM-whole) showed high performance in both training (area under the receiver operating characteristic curve [AUC] = 0.973) and validation cohorts (AUC = 0.985). Similarly, the feature-based combination model from the peripheral tumor (RM-peri) discriminated between immune-desert and excluded tumors with high performance in both training (AUC = 0.993) and validation cohorts (AUC = 0.984). Both RM-whole and RM-peri demonstrated good to excellent performance for every molecular subtype. Furthermore, in patients who underwent neoadjuvant chemotherapy (n = 64), pre-treatment images showed that tumors exhibiting complete response to neoadjuvant chemotherapy had significantly higher scores from RM-whole and lower scores from RM-peri. Our RMs predicted the immunophenotype of breast cancer based on the spatial distribution of CD8 T cells with high accuracy. This approach can be used to stratify patients non-invasively based on the status of the tumor-immune microenvironment.
Radiogenomics: bridging the gap between imaging and genomics for precision oncology.
He W, Huang W, Zhang L, Wu X, Zhang S, Zhang B MedComm (2020). 2024; 5(9):e722.
PMID: 39252824 PMC: 11381657. DOI: 10.1002/mco2.722.
Fan Y, Li X, Zhong P, Guo H, Han D, Tian W Balkan Med J. 2024; 41(3):213-221.
PMID: 38700366 PMC: 11077930. DOI: 10.4274/balkanmedj.galenos.2024.2024-2-64.
Lin G, Wang X, Ye H, Cao W Technol Cancer Res Treat. 2023; 22:15330338231218227.
PMID: 38111330 PMC: 10734346. DOI: 10.1177/15330338231218227.